These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12399186)

  • 1. Yellow fever vaccine safety: a reality or a myth?
    Arya SC
    Vaccine; 2002 Nov; 20(31-32):3627-8. PubMed ID: 12399186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates.
    Tyagi P; Ganguly M; Manney S; Wadkar K; Ingle N; Gairola S; Dhere R; Koide F; Grimes S
    Vaccine; 2023 Jan; 41(3):836-843. PubMed ID: 36564277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever vaccine: past, present and future.
    Roukens AH; Visser LG
    Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
    Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
    Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.
    Barrett AD; Monath TP; Barban V; Niedrig M; Teuwen DE
    Vaccine; 2007 Apr; 25(15):2758-65. PubMed ID: 17368349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
    Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.
    Marchevsky RS; Freire MS; Coutinho ES; Galler R
    Virology; 2003 Nov; 316(1):55-63. PubMed ID: 14599790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
    Camacho LA; de Aguiar SG; Freire Mda S; Leal Mda L; do Nascimento JP; Iguchi T; Lozana JA; Farias RH;
    Rev Saude Publica; 2005 Jun; 39(3):413-20. PubMed ID: 15997317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of the 17D-204 yellow fever vaccine.
    Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F
    Vaccine; 2015 Oct; 33(41):5432-5436. PubMed ID: 26314624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.
    Galler R; Pugachev KV; Santos CL; Ocran SW; Jabor AV; Rodrigues SG; Marchevsky RS; Freire MS; Almeida LF; Cruz AC; Yamamura AM; Rocco IM; da Rosa ES; Souza LT; Vasconcelos PF; Guirakhoo F; Monath TP
    Virology; 2001 Nov; 290(2):309-19. PubMed ID: 11883195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of interference by zoster vaccine with the immune response to yellow fever vaccine.
    Stier DM; Weber IB; Staples JE
    J Travel Med; 2012; 19(2):122-3. PubMed ID: 22414038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study.
    Kernéis S; Launay O; Ancelle T; Iordache L; Naneix-Laroche V; Méchaï F; Fehr T; Leroy JP; Issartel B; Dunand J; van der Vliet D; Wyplosz B; Consigny PH; Hanslik T
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1522-8. PubMed ID: 23554297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines and vaccination against yellow fever. WHO position paper -- June 2013.
    Wkly Epidemiol Rec; 2013 Jul; 88(27):269-83. PubMed ID: 23909008
    [No Abstract]   [Full Text] [Related]  

  • 19. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccines and international travelers.
    Barnett ED; Wilder-Smith A; Wilson ME
    Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.